Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

Subcutaneous Delivery of a Natural Asp-tRNA Synthetase Fragment Targeting Myofibroblasts Shows Strong Exposure and Reduced Markers of Lung Inflammation

Monday, February 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising results of a study on a natural Asp-tRNA synthetase fragment that targets myofibroblasts. The study highlights strong exposure following subcutaneous delivery and a reduction in lung inflammation markers. These findings suggest potential therapeutic benefits for conditions like pulmonary sarcoidosis and SSc-ILD.
Price reaction · baseline $0.899 (2026-02-06 close) · hit pre-market · clean, no other ATYR news in the window
day 0 close
+0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong exposure of the treatment observed.
  • Reduced markers of lung inflammation noted.
  • Potential for effective subcutaneous delivery.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is the focus of the study?

The study focuses on a natural Asp-tRNA synthetase fragment targeting myofibroblasts.

What were the results of the treatment?

The treatment showed strong exposure and reduced markers of lung inflammation.

How was the treatment delivered?

The treatment was delivered subcutaneously.

What conditions could benefit from this treatment?

Conditions like pulmonary sarcoidosis and SSc-ILD could benefit from this treatment.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare lung inflammation myofibroblasts subcutaneous delivery Efzofitimod
Last updated: Feb 9, 2026

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →